Clinical Trial Search

Primary: Number of Dose-limiting Toxicity (DLT) Events of Ipilimumab Plus a Fixed Dose of SD-101 (1 mg/Week) — 0 Dose-limiting toxicity events

Primary: Safety and Feasibility of TTR Closed-loop Control System as Measure by the Count of Successful Hospital Admissions — 7; 4; 7; 2 Admissions

Primary: Summed Pain Intensity Difference Over the First 48 Hours (SPID48) — -6956.0; -4829.3 units on a scale — p=0.0034

Primary: Mean Area of Skin Erythema (Skin Redness) — 3.968; 1.739 centimeters^2

Primary: Polyp Number — 22.6; 18.6 polyps — p=0.58

Primary: Premature Ejaculation Diagnostic Tool (Total Score) — 14.5; 13.7; 13.7; 8.9 scores on a scale

Primary: Heart Rate Assessments Upto Day 7 (Part B) — 87.4; 97.7; 87.9; 95.3 Beats per minute

Primary: Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131 — 86.8 Percentage of participants

Primary: Mean Change From Baseline in Central Retinal/Lesion Thickness (CRLT) as Measured by the Carl Zeiss Meditec Stratus Optical Coherence Tomography (OCT) Scanner at Day 29…

Primary: Percent (%) Change in 25(OH)D 5 Days Following Supplementation With 100,000 IU Cholecalciferol — 8; -2 percent change in 25(OH)D

Primary: Change in Serum 25(OH)D — 25; 33 ng/ml

Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants

Primary: Effects of PEGPH20

Primary: Patient Satisfaction — 259; 222; 37; 66 Participants

Primary: Change From Baseline in Composite Score of CSSB Following Dosing With GSK239512 — 0.065; 0.016; 0.086; 0.104 Scores on a scale — p=0.7239